39m
Bio-Rad outlines 2026 currency-neutral revenue growth of -3% to +0.5% amid Middle East disruption
Q1 2026 earnings call recap: guidance cut on Middle East headwinds, ddPCR/QX700 momentum, margins & FCF outlook—read key takeaways.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results